Citation notice #8487 · 2026-08-05 06:18:38.113482+00:00
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
Correction
Crossref
Open
cites 10.1016/s0140-6736(19)32591-7, which carries a correction notice dated 2021-06-10. One-hop deterministic notice: the citation edge exists in the Pith bibliography graph; no model judged whether the citation was load-bearing.
Citing paper Event page Original DOI Notice DOI File a formal challenge All reference changes
01Evidence
Raw extraction · bibliography line · bibliography index 25
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
02Event
- Type
- Correction
- Source
- Crossref
- Original DOI
- 10.1016/s0140-6736(19)32591-7
- Notice DOI
- 10.1016/s0140-6736(21)01119-3
- Date
- 2021-06-10
- Title
- Department of Error
- Reasons
- ['Erratum']
- Work
- - (2019) The Lancet
03Dispute this notice
If this citation does not depend on the flagged claim, or the event is wrong, say so. Disputes are public. For a signed challenge against the paper itself, use the formal challenge form.